» Articles » PMID: 17382827

The SANAD Study of Effectiveness of Carbamazepine, Gabapentin, Lamotrigine, Oxcarbazepine, or Topiramate for Treatment of Partial Epilepsy: an Unblinded Randomised Controlled Trial

Abstract

Background: Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes.

Methods: SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748.

Findings: For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0.78 [95% CI 0.63-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.52-0.79]), and had a non-significant advantage compared with oxcarbazepine (1.15 [0.86-1.54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0.75 [0.63-0.90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [0.73-1.18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine.

Interpretation: Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures.

Citing Articles

Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study.

Strzelczyk A, von Podewils F, Hamer H, Knake S, Rosenow F, Klotz K CNS Drugs. 2025; 39(3):321-331.

PMID: 39954117 PMC: 11850496. DOI: 10.1007/s40263-025-01158-8.


Polymorphism and Pharmacological Assessment of Carbamazepine.

Sa Filho A, Martins J, Costa R, Pedrino G, Duarte V, Silva O Int J Mol Sci. 2024; 25(18).

PMID: 39337323 PMC: 11431949. DOI: 10.3390/ijms25189835.


Running Out of Breath: The Diminishing Role of Gabapentinoids in Epilepsy.

Lapalme-Remis S Epilepsy Curr. 2024; 24(4):265-267.

PMID: 39309063 PMC: 11412391. DOI: 10.1177/15357597241253505.


One for All-Can We Have and Do We Want a First-Line Monotherapy for Epilepsy?.

Steriade C Epilepsy Curr. 2024; 24(2):108-110.

PMID: 39280050 PMC: 11394409. DOI: 10.1177/15357597241227655.


Anti-seizure medication prescription preferences: a Moroccan multicenter study.

Naji Y, Hrouch W, Laadami S, Adali N Front Neurol. 2024; 15:1435075.

PMID: 39246605 PMC: 11378524. DOI: 10.3389/fneur.2024.1435075.


References
1.
Brodie M, Chadwick D, Anhut H, Otte A, Maton S, Sauermann W . Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002; 43(9):993-1000. DOI: 10.1046/j.1528-1157.2002.45401.x. View

2.
Marson A, Kadir Z, Chadwick D . New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ. 1996; 313(7066):1169-74. PMC: 2352473. DOI: 10.1136/bmj.313.7066.1169. View

3.
French J, Kanner A, Bautista J, Abou-Khalil B, Browne T, Harden C . Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American.... Neurology. 2004; 62(8):1252-60. DOI: 10.1212/01.wnl.0000123693.82339.fc. View

4.
Jones B, Jarvis P, Lewis J, Ebbutt A . Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996; 313(7048):36-9. PMC: 2351444. DOI: 10.1136/bmj.313.7048.36. View

5.
. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981; 22(4):489-501. DOI: 10.1111/j.1528-1157.1981.tb06159.x. View